Deep search
Search
Images
Videos
Maps
News
Shopping
Copilot
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Medicare to negotiate price of Ozempic, Wegovy weight-loss drugs
The Biden administration moved Friday to negotiate the prices Medicare pays for the blockbuster weight-loss drugs Ozempic and Wegovy, medications costing the massive government health program billions of dollars a year.
Ozempic, Wegovy among drugs selected for Medicare's price negotiations
The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare Part-D for price negotiations, the next round of negotiations under the Inflation Reduction Act passed by President Joe Biden in 2022.
Medicare’s Selection Of 15 More Drugs For Price Negotiation Puts Spotlight Back On IRA
The 15 drugs selected for negotiation are prescribed to 5.3 million Medicare beneficiaries to treat conditions ranging from cancer and type 2 diabetes to asthma.
Explainer: What Wegovy's inclusion in Medicare price negotiation means for patients, company
The U.S. government on Friday announced a list of 15 prescription medicines targeted for Medicare price negotiations for 2027, which includes Novo Nordisk's blockbuster weight-loss drug Wegovy. Here's
Ozempic among drugs targeted in upcoming Medicare price negotiations
Novo Nordisk’s blockbuster diabetes and weight-loss drugs Ozempic and Wegovy are among a group of 15 drugs set to be affected by the next round of US government price negotiations by Medicare. The group of drugs accounted for about $41bn in annual spending by Medicare,
Ozempic Among the Next Drugs Up for Medicare Price Negotiations
The U.S. government named 15 drugs that will be subject to the second round of price negotiations by Medicare, including Ozempic and Wegovy, the drugs at the center of the weight-loss craze. The Biden administration said the drugs account for $41 billion in annual Medicare spending,
Novo's Ozempic, Wegovy picked for US Medicare price negotiations
Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for Medicare price negotiations for 2027, the U.S. government said on Friday, part of a law pharmaceutical companies have pledged to revisit with the Trump administration.
Medicare announces 15 new drugs chosen for price negotiations, including popular weight loss drug Ozempic
Diabetes and weight loss drugs Ozempic and Wegovy have been added to the list of medications selected for Medicare price negotiations, federal health officials announced Friday. The negotiations for the 15 additional drugs,
pharmaphorum
1d
Tackling inappropriate prescription practices for weight loss drugs
Mounjaro, like other GLP-1 drugs, carries potential side effects, including nausea, vomiting, dehydration, and hypoglycaemia ...
10d
Polls On Weight Loss And Will Power
Polls provide a useful window into understanding how Americans view their own weight and the recent availability of drugs ...
1d
E-sellers of compounded weight-loss drugs fail to reveal risks, research shows
Websites selling compounded versions of popular weight-loss drugs from Novo Nordisk and Eli Lilly to U.S. consumers often do ...
7d
FDA Approves Weight-loss Drug Zepbound For Sleep Apnea – Will Insurance Cover This $1000-Per-Month Medication?
Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...
3d
Obesity label is medically flawed, says global report
Calling people obese is medically "flawed" - and the definition should be split into two, a report from global experts says.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback